Go Deep
Bionano Genomics, Inc.
Bionano Genomics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,571 | -0.5 | 0.51 | 0.21 | 129.76 |
| Oct 2026 | 20,862 | -0.4 | 0.47 | 0.21 | 118.39 |
| Oct 2026 | 20,935 | -0.4 | 0.46 | 0.21 | 115.68 |
| Oct 2026 | 20,874 | -0.4 | 0.46 | 0.21 | 118.05 |
| Oct 2026 | 20,862 | -0.4 | 0.47 | 0.21 | 118.23 |
| Oct 2026 | 21,032 | -0.4 | 0.44 | 0.21 | 111.38 |
Bionano Genomics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 8,171,000.0 | 6,687,000.0 | 7,951,000.0 | 7,367,000.0 |
| Net Profit | -7,423,000.0 | -8,303,000.0 | -7,933,000.0 | -8,503,000.0 |
| EPS | -0.6 | -0.8 | -0.7 | -0.9 |
Bionano Genomics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 28,508,000.0 | 30,776,000.0 | 36,116,000.0 | 27,802,000.0 | — |
| Net Profit | -26,395,000.0 | -112,017,000.0 | -232,493,000.0 | -132,596,000.0 | — |
| EPS | -2.5 | -60.0 | -408.6 | -267.7 | — |
Bionano Genomics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 73,584,000.0 | 76,670,000.0 | 214,404,000.0 | 307,502,000.0 | — |
| Total Liabilities | 29,160,000.0 | 41,295,000.0 | 118,247,000.0 | 58,104,000.0 | — |
| Total Equity | 44,424,000.0 | 35,375,000.0 | 96,157,000.0 | 249,398,000.0 | — |
Owes vs Owns
Bionano Genomics, Inc. owed $0.34 for every $1 it owned in Jun 2026, up from $0.19 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.34× | 0.40× | 0.54× | 0.55× | 0.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Bionano Genomics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 26.2%Receivables 7.1%Inventory 7.4%Fixed assets (tangible) 28.8%Intangible assets 5.9%Other assets 24.7%
How it's funded — Dec 2025
Short-term debt 1.3%Long-term debt 8.1%Payables 7.6%Other liabilities 22.6%Shareholders' equity 60.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 19.3 | 9.5 | 66.8 | 113.2 |
| Receivables | 5.2 | 4.8 | 9.7 | 7.5 |
| Inventory | 5.4 | 11.1 | 22.9 | 29.8 |
| Fixed assets (tangible) | 21.2 | 24.3 | 32.5 | 29.0 |
| Intangible assets | 4.3 | 9.7 | 34.0 | 118.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 18.2 | 17.3 | 48.6 | 9.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.9 | 3.3 | 69.8 | 2.5 |
| Long-term debt | 6.0 | 3.7 | 7.2 | 9.1 |
| Payables | 5.6 | 7.0 | 10.4 | 12.5 |
| Other liabilities | 16.7 | 27.4 | 30.9 | 33.9 |
| Shareholders' equity | 44.4 | 35.4 | 96.2 | 249.4 |
| Net tangible assets | 40.1 | 25.7 | 62.2 | 131.0 |
Bionano Genomics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -16,345,000.0 | -68,922,000.0 | -125,181,000.0 | -124,816,000.0 | — |
| Investing Activities | -12,747,000.0 | 73,839,000.0 | 24,158,000.0 | 82,767,000.0 | — |
| Financing Activities | 24,039,000.0 | -13,685,000.0 | 113,815,000.0 | 23,007,000.0 | — |